Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
Royalty Pharma plc (Nasdaq: RPRX) has announced key promotions within its senior leadership team effective January 1, 2023. Sara Klymkowsky and Brienne Kugler are promoted to Senior Vice President, Research & Investments, recognized for their significant contributions to major transactions since they joined the company in 2012 and 2014, respectively. Alessandra Sassun is appointed Senior Vice President, Head of Human Capital, bringing experience in human resources. CEO Pablo Legorreta expressed confidence that this strengthened leadership will enhance Royalty Pharma's mission in life sciences innovation and stakeholder value.
Royalty Pharma plc (Nasdaq: RPRX) is set to join the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022, at 10:30 a.m. ET. Investors can access the live webcast via Royalty Pharma’s “Events” page, where it will be archived for at least 30 days.
Royalty Pharma, founded in 1996, specializes in acquiring biopharmaceutical royalties. The company collaborates with various innovators across the biopharmaceutical sector and currently holds royalties for over 35 commercial products, enhancing the funding of innovation within the industry.
Royalty Pharma (Nasdaq: RPRX) has acquired a royalty interest in Amgen's olpasiran from Arrowhead Pharmaceuticals for $250 million in cash, with potential additional payments up to $160 million based on certain milestones. Olpasiran, developed to reduce lipoprotein(a) levels associated with cardiovascular diseases, has shown promise in Phase 2 studies. Arrowhead retains rights to $400 million in milestone payments from Amgen. This acquisition reinforces Royalty Pharma's strategy to invest in innovative therapies targeting unmet medical needs.
Arrowhead Pharmaceuticals has announced that Royalty Pharma has acquired a royalty interest in Amgen's olpasiran for $250 million upfront, plus up to $160 million in additional payments based on milestones. Olpasiran, developed for cardiovascular disease treatment, is approaching Phase 3 trials. Arrowhead retains rights to $400 million in milestone payments related to Amgen's development of olpasiran. This agreement reinforces the potential of olpasiran and supports Arrowhead's investment in its RNAi therapeutic pipeline.
Royalty Pharma (RPRX) reported Q3 2022 results showing net cash from operations of $539 million, up 15% year-over-year. Adjusted Cash Receipts increased 2% to $597 million. The company raised its full-year guidance for Adjusted Cash Receipts to between $2,750 million and $2,800 million, reflecting positive performance driven by royalty acquisitions and existing product sales, particularly in the cystic fibrosis and oncology sectors. Notably, transactions year-to-date have reached $3.0 billion, highlighting ongoing growth and market demand.
Royalty Pharma plc (RPRX) will announce its third quarter 2022 financial results on November 8, 2022, before U.S. markets open. A conference call will follow at 8:00 a.m. Eastern Time, accessible via the company's website. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation in the sector, holding royalties on over 35 commercial products. These include notable therapies like Vertex's Trikafta and Biogen's Tysabri. For further details, visit the company's investors page.
The board of directors of Royalty Pharma plc (RPRX) has declared a fourth quarter 2022 dividend of $0.19 per Class A ordinary share. This dividend will be disbursed on December 15, 2022, to shareholders who are on record by the close of business on November 18, 2022. Royalty Pharma, founded in 1996, is a significant player in the biopharmaceutical industry, known for acquiring royalties and funding innovations aimed at advancing treatments. The company boasts a diverse portfolio, which includes royalties from over 35 leading therapies.
Royalty Pharma has announced key changes to its leadership team, appointing Art McGivern as Executive Vice President, Investments & General Counsel, while promoting George Lloyd to Executive Vice President, Investments & Chief Legal Officer. McGivern joins from Goodwin Procter with extensive experience in transaction structuring in the life sciences sector. Lloyd, who has been with the company since 2011, will oversee the legal team as responsibilities increase due to the complexity of transactions. These changes aim to enhance Royalty Pharma's capacity to navigate its growing transaction pipeline.
Royalty Pharma has partnered with Merck to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor for treating schizophrenia. Royalty Pharma will provide $50 million upfront, with an option for an additional $375 million if Merck proceeds to Phase 3 trials. This unique collaboration showcases Royalty Pharma's commitment to innovative funding solutions and reflects the unmet need for new schizophrenia treatments. The partnership positions Royalty Pharma as a key player in biopharmaceutical funding, enhancing its pipeline of promising therapies.
Royalty Pharma plc (Nasdaq: RPRX) is set to participate in several investor conferences this September. Key dates include Citi’s 17th Annual BioPharma Conference on September 8 at 11:20 a.m. ET, Morgan Stanley’s Global Healthcare Conference on September 12 at 10:30 a.m. ET, and Bank of America’s Healthcare Conference on September 15 at 10:55 a.m. ET. Webcasts will be available on Royalty Pharma’s Events page and archived for thirty days. The company, established in 1996, is the leading buyer of biopharmaceutical royalties, focusing on funding innovation across the industry.
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
